EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal

Snyder Brett iD, Miller Taylor iD, McCormick Pamela, Gionfriddo Michael

Clinical and Applied Thrombosis/Hemostasis · 2024

DOI: 10.1177/10760296241243368 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2024. Verfasst von Snyder Brett und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, UPMC Mercy, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Blood Coagulation Factors, Factor Xa Inhibitors, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Our institution introduced fixed-dose prothrombin complex concentrate (PCC) to streamline order verification and medication administration. Previous studies using fixed-dose PCC for vitamin K antagonist reversal showed comparable efficacy to weight-based dosing.

Objective

To compare fixed versus weight-based PCC dosing for reversal of Factor Xa Inhibitor (FXaI) effects.

Methods

Retrospective cohort study conducted at a tertiary care academic medical center. Patients who received PCC to reverse the effects of apixaban or rivaroxaban were eligible. Subjects in the fixed-dose group (5000 units or 2000 units) were compared to weight-based PCC (50 units/kg). The primary outcome was time between order entry and medication administration. Secondary outcomes included: average PCC dose, postadministration procedures, achieved hemostasis, 30-day mortality, hospital length of stay, and adverse drug events.

Results

72 patients received fixed-dose PCC and 101 received weight-based PCC. Median time between order entry and administration was 4.5 min shorter in the fixed-dose group compared to weight-based (34.5 vs 39 min, P = .10). In patients who received fixed-dose, 79.2% achieved hemostasis versus 71.3% in the weight-based group (RR = 1.11, 95% CI = 0.94-1.32). There was no difference in the number of subsequent hemorrhage-related surgeries (29.2% vs 36.7%, RR = 0.80, 95% CI = 0.51-1.24) or mortality rate (26.4% vs 35.6%, RR = 0.73, 95% CI = 0.46-1.17). There were zero adverse drug events reported. Rates of thrombosis were 2.8% and < 1% ( P = .57) in the fixed and weight-based groups, respectively. Conclusion and Relevance: The fixed-dosing strategy did not reduce time to PCC administration nor impact hemostasis or mortality. These data support that the fixed-dosing method is a viable option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Coagulation FactorsFactor Xa InhibitorsPyrazolesHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPyridonesRivaroxaban

Stichwörter der Autor:innen

factor xa inhibitorsfixed-dosehemorrhageprothrombin complex concentratereversalweight-based

Substanzen

prothrombin complex concentratesBlood Coagulation FactorsFactor Xa InhibitorsPyridonesRivaroxabanapixabanPyrazoles

Autor:innen und Institutionen

  • Department of Pharmacy, UPMC Mercy, Pittsburgh, PA, USA.
  • School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.

ORCID-Profile: Snyder Brett, Miller Taylor

Zitieren

APA

Brett, S., Taylor, M., Pamela, M., & Michael, G. (2024). Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296241243368

Vancouver

Brett S, Taylor M, Pamela M, Michael G. Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal. Clinical and Applied Thrombosis/Hemostasis. 2024. doi:10.1177/10760296241243368

BibTeX
@article{Brett2024,
  author = {Brett, Snyder and Taylor, Miller and Pamela, McCormick and Michael, Gionfriddo},
  title = {Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2024},
  doi = {10.1177/10760296241243368}
}
Kostenlos starten →